Novartis (NYSE: NVS) announced that the European Commission has approved the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE